# Curiox Biosystems Pte

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/curiox-biosystems-pte

- Industry: Medical Devices & Equipment
- Headquarters: Singapore, Singapore
- Website: www.curiox.com
- Total disclosed funding: $37M
- Latest round: Series C (Jan 10, 2022)
- Investors on record: 8

## About

Curiox Biosystems Pte Ltd, based in Singapore, specializes in automated sample preparation technologies to enhance cellular analysis, focusing on innovative solutions for research and clinical applications.Curiox Biosystems Pte Ltd focuses on developing advanced technologies for automated sample preparation. Founded in 2008 in Singapore, the company has raised a total of KRW 17.1 billion, with its most recent funding round being Series C in January 2022, led by Luha Private Equity and supported by KB Investment and QUAD Ventures. The CEO, Namyong Kim, has a background in biotechnology and has previously founded other ventures. The company has conducted 5 deals to date.Curiox Biosystems specializes in advanced automated sample preparation technologies designed to enhance cell analysis. The company’s flagship offering is the C-FREE technology, which utilizes laminar flow principles for gentle washing of cell and bead samples, thus enabling automation within a simple pipette robot workstation. This innovative approach replaces traditional centrifugation methods, allowing for a broader range of sample types and compatibility with standard-format consumables. Their products are tailored for use in various applications, including flow cytometry, single-cell sequencing, mass cytometry, and multiplex immunoassays. The primary customer base consists of research institutions, hospitals, and laboratories focused on hematological malignancies and broader cellular analysis. Curiox’s solutions are marketed primarily in North America and Europe, where the demand for efficient and reproducible cell processing workflows is critical.Curiox Biosystems generates revenue through direct sales of its automated sample preparation solutions and consumables to research institutions and clinical laboratories. In the most recent fiscal year, the company reported revenue of KRW 839,218.70 and an EBITDA of KRW -350,733.70. The company typically engages in B2B transactions, providing tailored solutions that enhance laboratory workflows and efficiency. Transactions are structured as one-time purchases for equipment, along with recurring sales of consumables necessary for operation, which may include reagents and other materials essential to their technologies. The focus on providing comprehensive solutions for advanced cellular analysis underscores the potential for sustained revenue growth within niche markets in North America and Europe.In January 2022, Curiox Biosystems raised KRW 17.1 billion in Series C funding, which will be used to expand the lineup of cell pre-treatment automation equipment and support new product developments aimed at disease diagnosis. The company is targeting expansion into additional markets across Asia and Europe by the end of 2023. This funding round attracted interest from various venture capital operators, indicative of the growing potential in these areas.

## Funding rounds

- Series C, Jan 10, 2022, $14M — KB Investment, QUAD Ventures, Luha Private Equity
- Series B, Oct 16, 2019, $15M — KB Investment, HB Investment, IMM Investment, SV Investment, QUAD Ventures, DAYLI Partners
- Series A, Dec 28, 2018, $7.4M — ZIG Ventures

## Investors

- ZIG Ventures (https://capitalatlas.ai/funds/zig-ventures) — Series A
- KB Investment (https://capitalatlas.ai/funds/kb-investment) — Series B, Series C
- HB Investment (https://capitalatlas.ai/funds/hb-investment) — Series B
- IMM Investment (https://capitalatlas.ai/funds/imm-investment) — Series B
- SV Investment (https://capitalatlas.ai/funds/sv-investment) — Series B
- QUAD Ventures (https://capitalatlas.ai/funds/quad-ventures) — Series B, Series C
- DAYLI Partners (https://capitalatlas.ai/funds/dayli-partners) — Series B
- Luha Private Equity (https://capitalatlas.ai/funds/luha-private-equity) — Series C